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Capillary deposition of C4d complement fragment and early renal graft
loss. Clinical outcome of kidney grafts that are affected by the complex
syndrome of 'early graft dysfunction' is uncertain and rather unpredict-
able. In this study, an individual prognosis for dysfunctioning allografts
(N = 93) is attempted by the immunohistological assessment of vascular
classical complement activation in graft biopsies. Thus, capillary dep-
osition of complement fragment C4d was observed in the majority (N =
51) of early dysfunctioning grafts. In 43 biopsies, abundant deposition
of fragment C4d was present in all capillaries, whereas in eight
specimens a segmental distribution of capillary C4d was observed. In 42
grafts with early dysfunction no capillary C4d was detectable. Eighteen
subsequent graft losses within one year (16 early losses) were recorded
in the subgroup with C4d in all capillaries, and three early losses in the
group with segmentally distributed C4d. Only four graft losses (3 early
losses) were recorded in the C4d-negative group (P = 0.0027; Pearson's
chi square test). The resulting one-year graft survival rates (72% for the
study group) differed markedly between the subgroups. Grafts with
generalized or segmental capillary deposition of C4d had 57% and 63%
survival, respectively, contrasted by 90% survival in the C4d-negative
group. It is of note, however, that also three of the four grafts that were
finally lost within the C4d-negative group, showed distinct capillary
deposition of C4d in second biopsies. Vascular deposition of comple-
ment fragment C4d therefore represents a clinically relevant factor that
contributes to early graft dysfunction. Its assessment is helpful for an
individual graft prognosis.
The early post-transplantation period is critical for later
clinical outcome of renal grafts in allogeneic recipients [1].
During this period, more than one-third of cadaver allografts are
either not functioning at all, or show some other degree of
dysfunction. Among the most frequent causes of true graft
dysfunction (after exclusion of mechanical factors) are: func-
tional impairment owing to detrimental donor conditions, to
impaired organ preservation, to rejection episodes, to drug
toxicity or to a combination of them [2]. Postoperative biopsies
from dysfunctioning grafts are usually performed within two
weeks in order to determine reversible or remediable condi-
tions. However, the interpretation of histopathological findings,
in particular the distinction between different pathological en-
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tities, appears to be especially difficult at that time [3]. Since
reliable clinical and laboratory markers for an individual graft
prognosis are also lacking, the reasons for early graft losses
often remain obscure.
Recently, prominent deposition of 'early' complement split
products C4d and C3d has been observed within renal graft
capillaries in a substantial number of acute and chronic rejec-
tions [4]. Abundant complement deposition in interstitial capil-
laries was unique to allografts and could not be detected in
autologous normal or glomeri.tlonephritic kidneys. Vascular
deposits of C4d and C3d, indicating classical pathway activa-
tion, were only rarely accompanied by immunoglobulin depos-
its and terminal complement components C5-9. Because of its
association with preformed antibodies to HLA in recipients,
vascular presence of complement fragment C4d has finally been
assumed to represent an otherwise undetectable humoral im-
mune reaction against graft endothelial cells.
To prove the clinical relevance of that finding, the question of
whether such presumed humoral immune reactions were corre-
lated with individual graft outcome is investigated in this study.
Thus, biopsies from grafts with early dysfunction were evalu-
ated for the vascular presence or absence of split product C4d
as a single criterion. The resulting subgroups were analyzed
with respect to graft survival.
Methods
Patients and graft biopsies
A total of 596 patients in this study received cadaver kidney
grafts in the Division of Transplant Surgery between January
1989 and June 1992. In 199 patients postoperative graft biopsies
were performed within four weeks because of early graft
dysfunction. Early graft dysfunction was defined as either
primary non-function (persisting oligo-/anuria) or any other
functional impairment within four weeks after transplantation
(after mechanical factors have been excluded by clinical and
radiological diagnostic techniques). From 100 unselected first
biopsies (mean interval after transplantation: 11 days) either
snap-frozen tissue specimens (N = 52) or cryostat sections (N
= 48) were transferred to the Institute of Immunology for the
immunohistological assessment of complement deposition.
From these, 93 specimens could be evaluated. From 16 grafts
1333
1334 Feucht et a!: Complement fragment C4d and renal graft loss
second biopsies were obtained two to four weeks later. Depo-
sition of C4d was assessed in all specimens by indirect immu-
noperoxidase staining without knowledge of histopathological
diagnoses. Diagnostic classification of graft biopsies followed
standard histopathological criteria [5, 61.
immunosuppressive therapy
Immunosuppressive therapy in recipients was started either
with a triple drug regimen (cyclosporine, steroids, azathioprine)
or, in patients with immunological risk factors (presence of
panel reactive antibodies and/or previously rejected grafts),
with a quadruple drug regimen (supplemented with polyvalent
or monoclonal anti-lymphocyte antibodies). Rejections were
treated with high-dose steroids for three days, and if unrespon-
sive, with anti-lymphocyte antibodies (polyvalent or mono-
clonal preparations).
Crossmatch technique and assessment of panel reactive
antibodies
Serological HLA typing has been described in detail else-
where [7]. All recipient sera produced a negative crossmatch
test with donor lymphocytes before transplantation. Cross-
matches were performed according to the rules of the Euro-
transplant Organization using the standard microcytotoxicity
technique of Terasaki and McClelland [8]. The crossmatches
were performed with peripheral lymphocytes (mixture of T and
B cells) with a prolonged incubation time of two hours with
complement. Crossmatches with historic serum samples of the
patients were not performed. According to the rules of Euro-
transplant the sera of recipients on the waiting list were
screened four times a year for the presence of lymphocytotoxic
antibodies and positive serum samples were investigated with a
total of 150 typed lymphocyte samples in order to determine the
antibody specificity. Antibody specificities found in the serum
of a prospective recipient led to the exclusion of all kidneys
possessing that particular antigen. A panel reactivity of greater
than 30% was classified as "immunological risk," and a reac-
tivity greater than 84% as "highly immunized."
Immunoperoxidase staining
Indirect immunoperoxidase staining was performed as de-
scribed previously [4]. In brief, 4 sm cryostat sections (air-
dried, fixed in cold acetone (Merck, Darmstadt, Germany),
washed in phosphate buffered saline (PBS) at pH 7.4 were
reacted serially with appropriately diluted primary monoclonal
antibodies and with peroxidase-conjugated second antibody
(rabbit anti-mouse immunoglobulins; Dakopatts, Hamburg,
Germany). Sections were finally stained with 3-amino-9-ethyl-
carbazole (Sigma, MUnchen, Germany), DMSO, H202 (Merck)
and counterstained with hemalaun (Merck). For microscopic
evaluation, sections were mounted with glycerin-gelatin
(Merck). As a control, sections were incubated with superna-
tants from irrelevant isotype-defined mouse hybridomas or
non-immune goat or rabbit 1g.
Monoclonal antibodies
From our own panel of mouse monoclonal antibodies (mAbs)
reactive with the C4d (a2) portion of human complement
component C4, mAbs M4d2 and M4d3 [9, 101, together with a
commercially available mAb against C4d (Byk-Sangtec,
Munchen, Germany) were used in parallel in a first series of 30
biopsies. Since identical staining results were obtained, mAb
M4d2 was used subsequently throughout the study.
To ascertain the presence of capillaries in a biopsy specimen
and to determine their approximate number, one of several
commercially available mAbs reactive against vascular endo-
thelial cells were used in parallel sections throughout the study:
PAL-E and EN 4 (Sanbio, Uden, The Netherlands); BMA 120
(Behringwerke, Marburg, Germany); anti-human factor-Vill
related antigen (Immunotech S.A., Marseille, France).
Data monitoring and statistical analysis
Patient data were monitored with computer assistance using
the ENABLE data processing tools (Markt & Technik, Haar,
Germany). Graft survival rates were computed by the Cutler-
Ederer method [11]. For statistical comparison, Pearson's chi
square test, Cochran's test for linear trend and Fisher's exact
test were calculated using the BMDP 4F program.
Results
Distribution of complement fragment C4d in graft capillaries
Assessment of capillary deposition of complement fragment
C4d in graft biopsies revealed three staining patterns. Graft
biopsies were subdivided into three groups according to depo-
sition of C4d in interstitial capillaries: biopsies were assigned
C4d+ when all capillaries showed deposition of C4d; C4d(+)
indicates segmental staining of capillaries; C4d— denotes ab-
sent staining in capillaries (Fig. 1).
Table 1 denotes the numerical distribution of first biopsies
among the C4d+ (N = 43), C4d(+) (N = 8) and C4d— (N = 42)
subgroups. Second biopsies were available from 16 grafts, and
six specimens were initially classified as C4d+ and remained so
in the repeat samples, whereas 5 out of 10 grafts within the
C4d— group clearly changed into C4d+ and (+) patterns,
respectively (Fig. 2).
The corresponding histological diagnoses in parallel speci-
mens are given in Table 2. Grafts in the C4d+ group showed
more combinations of cellular and vascular rejection and other
combined pathological findings, whereas interstitial cell-medi-
ated rejections were more frequent in the C4d— group. Grafts
with preservation injury were equally distributed among C4d+
and C4d— groups.
Distribution of donor and recipient risk factors
The distribution of several factors with possible impact on
ultimate graft outcome is given in Table 3. There were no
apparent differences among the subgroups with respect to
donor age, the number of donors with hypotensive episodes or
to cold ischemia times. The subgroups also had comparable
mismatches in three HLA loci (A, B and DR). The C4d+ group
contained more recipients with conventional immunological
risk factors (> 30% panel reactivity of preformed antibodies to
HLA and/or previously rejected transplants) who received a
quadruple immunosuppressive induction therapy (N = 25 vs. 7
in the C4d— group). More subsequent anti-rejection treatments
with mono- or polyclonal anti-lymphocyte antibodies were
applied in the C4d— group, therefore the total number of
patients receiving one or two courses of antibody therapy was
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Fig. 1. Patterns of capillary deposition of C4d in renal transplants with early dysfunction. (A) C4d+ pattern: staining of all interstitial and
glomerular capillaries; (B) C4d(+): segmental staining of interstitial (arrow) and glomerular capillaries; (C) C4d—: interstitial capillaries are
negative, glomerular deposits of C4d represent staining of normal glomeruli; (immunoperoxidase staining; magnification x 120).
Table 1. Deposition of complement C4d in 109 biopsies from 93 early
dysfunctioning grafts
Staining pattern of capillary
complement deposition
C4d+ C4d(+) C4d—
First biopsies (N) 43 8 42
mean 11 days after transplant
Second biopsies (2 to 4 weeks later)
from C4d+ grafts (N 6) 6 0 0
from C4d— grafts (N = 10) 2 3 5
comparable within the subgroups. It is interesting to note that
seven recipients in the C4d — groupwere biopsied after quadru-
pie induction therapy and five patients in this group (without
quadruple induction) were treated with anti-lymphocyte globu-
lins but remained C4d negative in subsequent biopsies. In the
C4d+ group, 10 patients (without quadruple induction) were
positive before they received anti-lymphocyte preparations.
Neither was capillary C4d associated with the prophylactic
application of anti-cytomegalovirus immunoglobulins in 8 recip-
ients.
Mean serum creatinine concentrations at the time of first
biopsy did not differ markedly between the groups, indicating
comparable degrees of functional impairment. However, as
many as 18 graft losses within one year were recorded in the
C4d+ subgroup, compared with only four graft losses in the
C4d— group. In the small C4d(+) group three grafts were lost.
The association of capillary deposition of C4d with subsequent
graft loss was found to be statistically significant by calculating
both Pearson's chi square test (P = 0.0027) and Cochran's test
for linear trend (P = 0.0008).
Characterization of graft losses
In Table 4, the distribution of immunological risk factors and
histological diagnoses among the 25 graft losses is denoted. In
the C4d+ group, 13 grafts with primary non-function were
recorded, whereas four grafts in the C4d— group initially
showed impaired function. From a total of 32 recipients with
immunological risk factors, 25 were contained within the C4d+
group, 11 of whom lost their graft (11 re-transplants with 8
recipients having panel reactive antibodies). It should be noted
that 14 recipients without any pre-existing risk factors lost their
graft, including four patients from the C4d— group, and that all
grafts survived in seven recipients receiving quadruple drug
therapy in this group. Thus, using Fisher's exact test, there was
no significant correlation between the presence of immunolog-
ical risk factors and graft loss in this study.
The predominant histological entity in the C4d+ group was a
combination of cellular and vascular rejection, that was also
highly associated with subsequent graft loss (P = 0.0001;
Fisher's exact test). Interestingly, four specimens in the C4d+
group were initially classified as preservation injury, but three
clearly changed in pathology and developed rejection in later
biopsies (2 cellular rejections, 1 combined cellular and vascular
rejection). Likewise, two grafts with combined pathological
A C4d +
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Fig. 2. Deposition of C4d in consecutive hi opsies from one graft with early dysfunction and subsequent loss because of progressive rejection. (A)
Absence of C4d 10 days after transplantation; (B) prominent deposition of C4d in peritubular capillaries 24 days after transplantation (X 250).
Table 2. Histological diagnosesa and C4d staining patterns in 93 graft
biopsies
Capiliary complement
staining
C4d+ C4d(+) C4d—
First biopsies N 43 8 42
Acute rejections
Cell-mediated interstitial 8 6 25
Vascular 2 0 0
Cellular + vascular rejection 9 0 2
(including acute cellular arteritis)
Preservation injury
Combined pathological findings'
11
13
0
2
8
7
a Histological diagnoses refer to the predominant pathological lesions
in a given biopsyb In grafts without predominating lesion but showing any combina-
tion of cellular/vascular rejection with preservation injury or cyclospo-
rifle toxicity
findings in that group changed into predominant rejection (1
cellular, 1 combined cellular plus vascular rejection). It should
finally be noted that from four grafts that were lost in the C4d—
group because of rejection, one clearly changed into the C4d+
(Fig. 2) and two into the C4d(+) pattern. Thus, only one graft
out of 25 was lost without capillary deposition of complement
fragment C4d.
Graft survival rates in relation to capillary deposition of C4d
The one-year graft survival rate of all allogeneic kidney
transplantations (N = 596) performed during the study period
was 82%, whereas a less favorable one-year survival of 71%
was recorded for all grafts that were biopsied within four weeks
because of early dysfunction (N 199). The 93 unselected
patients in the complement study showed an almost identical
one-year graft survival rate of 72% (Fig. 3).
When these patients were further subdivided according to the
distribution of capillary C4d in first biopsies, marked differ-
ences appeared with a one-year graft survival rate of only 57%
in the C4d+ group (N = 43), 63% in the C4d(+) group (N = 8),
in contrast to the C4d— group (N = 42) that reached a one-year
graft survival of 90% (Fig. 4).
Table 3. Distribution of donor and recipient risk factors, therapeutic
regimens and graft losses among C4d+, C4d(+) and C4d— early
dysfunctioning grafts (N = 93)
Capillary complement staining
C4d+ C4d(+) C4d—
First biopsies N 43 8 42
Mean donor age years 41 15 42 11 37 13
Donors with hypotensive 16 3 21
episodes
Cold ischemia time hours 25 7 26 4 25 6
Mismatches in HLA-loci
(mean)
A 0,8 0.9 0.8
B 0.9 0.7 0.7
DR 0.4 0.4 0.3
Immunosuppressive therapy
Induction with quadruple 25 0 7
druga
Induction with triple drug 18 8 35
Subsequent anti-rejection 36 8 35
treatments
Steroids only 8 2 3
Plus antibodies 28 6 32
Total of patients receiving 38 6 36
antibodies
Serum creatinine
mean conc. p,mol/liter
at time of first biopsy 676 188 636 280 629 246
end of follow-up 200 141 143 22 164 83
(functioning grafts)
Graft losses (within one 18b 3b 4b
year)
a Recipients with immunological risk factors (panel reactive Ab to
HLA and/or previously rejected grafts)
b P = 0.0027 Pearson's chi square test
Discussion
Abundant deposition of 'classical' complement split products
in graft capillaries as shown in this and in an earlier study [4] is
a novel finding. It warrants re-evaluation of the role of comple-
ment, of a major biological clearance and defence system [12],
in transplantation. A favorable graft outcome in the absence of
complement deposition, compared with a significantly worse
outcome in its presence, indicates that vascular complement
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CapiIlary complement
staining
C4d+ C4d(+) C4d—
Graft losses (N = 25) 18 3 4
Early losses (<3 months) 16 3 3
Primary non-function 13 2 0
Later losses (3—12 months) 2 0 1
Pre-existing immunological risk
Re-transplants 11 0 0
with panel reactivity >30% 6 — —
with panel reactivity >84% 2 — —
Histological diagnosis in first biopsy
Cell-mediated interstitial rejection 2 2 2
Vascular rejection 1 0 0
Cellular ÷ vascular rejection 8 0 1
Preservation injury 4 0 0
subsequent change in pathology 3 — —
Combined pathology 3 1 l
subsequent change in pathology 2 1 1
deposition is representing not merely an epiphenomenon but
rather a clinically relevant factor.
Assessment of capillary complement fragment C4d is attained
by a simple and rapid immunohistological staining technique.
Using one of the various antibodies to vascular endothelial cells
in parallel, the percentage of C4d-positive capillaries can be
reliably estimated even in very small or ill-preserved biopsy
specimens.
Thus, complement was present in the majority of a represen-
tative cohort of grafts with early dysfunction, including all but
four subsequent graft losses. It can be deduced that immediate
humoral anti-graft reactions are quite frequent in this complex
clinical setting. That vascular deposition of complement was
the result of antibody treatment is highly unlikely, since in 22
recipients there was no association with the therapeutic appli-
cation of mono- or polyclonal anti-lymphocyte preparations.
Instead, association with circulating panel-reactive antibodies
[4] and the dynamics of complement deposition point to the
presence of preformed anti-endothelial cell antibodies that may
cause complement precipitation. It should be noted, however,
that complement deposition also occurred in the absence of any
measurable anti-HLA activity. The precise antigenic specificity
of these antibodies escaping conventional crossmatch and lym-
phocyte panel testing remains to be determined [13]. Con-
versely, complement deposition did not occur despite the
presence of conventional immunological risk factors. Thus,
vascular absence of C4d denotes a subgroup with favorable
graft prognosis even within the 'immunological risk' group,
known to have generally a poor prognosis [14]. As a conse-
quence, there seems to be a stronger association of graft loss
with complement deposition than with other risk factors.
In this context it is also worth noting that even within the
original C4d-negative group, three of four grafts showed distinct
capillary complement deposition in second biopsies before they
were lost. This suggests an ongoing humoral anti-graft reaction
following transplantation. (Whether the small group with seg-
mental deposition of complement C4d also belongs in this
category is not clear at the moment.)
In this study, only short-term effects with respect to capillary
complement deposition are recorded. Longer follow-up periods
are required to denote the long-term sequelae in grafts that
showed initial complement deposition but survived the first
year, and perhaps even more importantly, in grafts that were
subject to later humoral reactions.
By conventional HLA typing, there were no significant
differences with respect to HLA mismatches between the
C4d-positive and the C4d-negative subgroups. However, the
HLA class II molecules including HLA-DR, -DP, -DQ, that are
important constitutive and inducible antigens on endothelial
cells [15], deserve special attention. It will be interesting to
determine, for example, whether previously unrecognized mis-
matches for HLA-DR that can now be revealed by improved
DNA typing [16] would account for some of the humoral
immune reactions reported herein.
Despite differing numbers of quadruple induction therapies in
the groups, there were no apparent differences with respect to
the overall frequency and modality of subsequent anti-rejection
Table 4. Complement staining patterns, immunological risk factors
and histological diagnoses in 25 graft losses
"\.Total(N=93)
C4d (+) (N=8)
C4d + (N=43)
100
90
8070
60
°' 5040
30
20
10
0
-----------
63%
57%
a Grafts (N = 3) that changed from C4d— into C4d+/(+) staining
patterns in later biopsies
----.--.-f
0 1 2 3 4 5 6 7 8 9 10 11 12
Time, months
Fig. 4. Survival rates of early dysfunctioning grafts with complement
staining pattern C4d+, C4d(+) and C4d—.
All grafts (N—596)
All grafts with biopsy (N= 199) 71%
100
90
80
. 70
4030
20
10
0
0 1 2 3 4 5 6 7 8 9 10 11 12
Time, months
Fig. 3. Survival rates of all allogeneic cadaver kidney grafts trans-
planted during study period, of all grafts that were biopsied within four
weeks and of transplants included in complement study.
1338 Feuchi et a!: Complement fragment C4d and renal graft loss
treatments. The favorable graft outcome in the complement-
negative group permits speculation that split product C4d
separates 'pure' cell-mediated rejections responsive to therapy
from 'mixed' rejections that may be less responsive. Likewise,
grafts that showed initially either preservation injury or com-
bined pathological findings but developed rejection later, could
be identified on that basis. Thus, deposition of C4d in capillaries
might indeed serve as an early and sensitive marker of impend-
ing vascular injury, since the histopathological criteria of vas-
cular rejection [5, 6] usually refer to changes in arterioles or
other larger vessels that can be missing in a given specimen.
In conclusion, capillary deposition of complement fragment
C4d appears to reveal clinically relevant, but otherwise unde-
tectable humoral anti-graft reactions. Its assessment provides a
valuable prognostic marker for individual graft outcome and
helps to define patients that may require additional or alterna-
tive forms of immunosuppressive therapy.
Acknowledgments
This work was supported by the Deutsche Forschungsgemeinschaft
(SFB 217: C8); H.E.F. is recipient of a Hermann and Lilly Schilling
professorship. We appreciate the technical assistance of Mrs. G.
Schmid and Ms. E. Jeschke. We are indebted to Dr. A. KOnig (Med.
Klinik, Klinikum Innenstadt) for advice in statistical analysis.
Reprint requests to Dr. H.E. Feuchi, Medizinische Klinik, Kilnikum
Innenstadt, Universitãt Miinchen, Ziemssenstraf3e 1, D-8000 München
2, Germany.
References
1. United States Renal Data System 1991 Annual Data Report. Renal
Transplantation: Access and Outcomes. (editorial) Am J Kidney
Dis 18:61—73, 1991
2. TILNEY NL: The early course of a patient with a kidney transplant,
in Kidney Transplantation: Principles and Practice (3rd ed), edited
by MORRIS PJ, Philadelphia, Saunders, 1988, pp. 263—283
3. Covmi RB: Renal Allografts, in Diagnostic Immunopathology,
edited by COLVIN RB, BHAN AK, MCCLUSKEY RT, New York,
Raven Press, 1988, pp. 151—197
4. FEUCHT HE, FELBER E, GOKEL MJ, HILLEBRAND G, NATFER-
MANN U, BROCKMEYER C, HELD E, RIETI-IMULLER 0, LAND W,
ALBERT E: Vascular deposition of complement-split products in
kidney allografts with cell-mediated rejection. Clin Exp Immunol
86:464—470, 1991
5. PORTER KA: Renal transplantation, in Pathology of the Kidney (3rd
ed), edited by HEPTINSTALL RH, Boston, Little, Brown and
Company, 1983, vol. III, pp. 1455—1547
6. CROKER BP, SALOMON DR: Pathology of the renal allograft, in
Renal Pathology, edited by TISHER CC, BRENNER BM, Philadel-
phia, Lippincott, 1989, vol. II, pp. 1518—1586
7. ALBERT ED, BAUR MP, MAYR WR (EDITORS): Hisiocompatibility
Testing 1984. Berlin, Springer-Verlag, 1984
8. TERASAKI P1, MCCLELLAND JD: Microdroplet assay of human
serum cytotoxins. Nature 204:998—1000, 1964
9. ZWIRNER J, FELBER E, HERZOG V, RIETHMULLER 0, FEUCHT HE:
Classical pathway of complement activation in normal and diseased
human glomeruhi. Kidney ml 36:1069—1077, 1989
10. ZWIRNER J, FELBER E, SCHMIDT P. RIETHMULLER G, FEUCHT
HE: Complement activation in human lymphoid germinal centres.
Immunology 66:270—277, 1989
11. CUTLER S, EDERER F: Maximum utilization of the lifetable method
in analyzing survival. J Chronic Dis 8:699—712, 1958
12. GALLAGHER RB (EDITOR): The biology of complement. Immunol
Today 12:291—342, 1991
13. Antibodies as a barrier to kidney transplantation. (editorial) Lancet
1:357—358, 1989
14. KEOWN PA: The highly sensitized patient: Aetiology, impact and
management. Transplant Proc 19:74—78, 1987
15. KOENE RAP, DE WAAL RMW, BOGMAN MJJT: Variable expres-
sion of major histocompatibility antigens: Role in transplantation
immunology. Kidney mt 30:1—8, 1986
16. OPELZ G, MYTILINEOS J, SCHERER 5, DUNCKLEY H, TREJAUT J,
CHAPMAN J, MIDDLETON D, SAVAGE D, FISCHER 0, BIGNON JD,
BENSA JC, ALBERT E, NOREEN H: Survival of DNA HLA-DR
typed and matched cadaver kidney transplants. Lancet 338:461—
463, 1991
